Get the Stockscreener App
6.72
6.67%
0.42
After Hours:
6.99
0.27
+4.02%
Champions Oncology Inc stock is traded at $6.72, with a volume of 12,363.
It is up +6.67% in the last 24 hours and down -2.18% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$6.30
Open:
$6.22
24h Volume:
12,363
Relative Volume:
0.65
Market Cap:
$92.66M
Revenue:
$49.98M
Net Income/Loss:
$-9.64M
P/E Ratio:
-9.4648
EPS:
-0.71
Net Cash Flow:
$-4.86M
1W Performance:
+11.26%
1M Performance:
-2.18%
6M Performance:
-9.13%
1Y Performance:
+30.23%
1-Day Range:
$6.22
$6.9999
1-Week Range:
$6.07
$6.9999
52-Week Range:
$4.9715
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
6.72 | 86.87M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Investors in Champions Oncology (NASDAQ:CSBR) from five years ago are still down 41%, even after 11% gain this past week - simplywall.st
Ocean Power Tech, Champions Oncology set to report earnings Monday By Investing.com - Investing.com Nigeria
Ocean Power Tech, Champions Oncology set to report earnings Monday - Investing.com
Insights Ahead: Champions Oncology's Quarterly Earnings - Benzinga
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025 - ACCESS Newswire
Shareholders in Champions Oncology (NASDAQ:CSBR) are in the red if they invested five years ago - Yahoo Finance
Will Champions Oncology Inc. (2I3) stock beat value stocks2025 Stock Rankings & Expert Curated Trade Setups - Newser
Will Champions Oncology Inc. stock deliver consistent dividendsJuly 2025 Review & AI Enhanced Trade Execution Alerts - Newser
Will Champions Oncology Inc. (2I3) stock outperform benchmarksInflation Watch & Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH) and Champions Oncology (CSBR) - The Globe and Mail
Why (CSBR) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Why Champions Oncology Inc. (2I3) stock is a strong buy callWeekly Trade Recap & Breakout Confirmation Alerts - Newser
Will Champions Oncology Inc. stock benefit from infrastructure spending2025 Performance Recap & Step-by-Step Swing Trade Plans - Newser
Why pension funds invest in Champions Oncology Inc. (2I3) stock2025 Top Gainers & Verified Short-Term Trading Plans - Newser
Will Champions Oncology Inc. (2I3) stock deliver stable dividendsJuly 2025 Trends & Weekly Return Optimization Alerts - Newser
What drives Champions Oncology Inc 2I3 stock priceMonthly Performance Summary & Achieve Triple Digit Returns - earlytimes.in
Patient-Derived Xenograft Model Market Size at USD 1.12 Billion in 2031, Forecasted to Grow at 13.4% CAGR Through 2031 | The Insight Partners (PR Newswire) - Aktiellt
Understanding Momentum Shifts in (CSBR) - news.stocktradersdaily.com
Will Champions Oncology Inc. stock outperform Nasdaq indexWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Quantitative breakdown of Champions Oncology Inc. recent move2025 Big Picture & Verified Entry Point Signals - newser.com
What dividend safety rating applies to Champions Oncology Inc. (2I3) stockDip Buying & Free Fast Entry Momentum Trade Alerts - newser.com
How Champions Oncology Inc. (2I3) stock behaves in tightening cycles2025 Pullback Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Candlestick signals on Champions Oncology Inc. stock todayJuly 2025 Levels & Risk Adjusted Swing Trade Ideas - newser.com
Published on: 2025-11-19 21:53:34 - newser.com
How Champions Oncology Inc. (2I3) stock reacts to weak economy - newser.com
Why Champions Oncology Inc. is moving todayPortfolio Growth Summary & Real-Time Buy Signal Alerts - newser.com
Is Champions Oncology Inc. stock a buy in volatile marketsEarnings Recap Summary & Short-Term High Return Strategies - newser.com
Champions Oncology, Inc.Common Stock (NQ: CSBR - FinancialContent
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):